Evidence map›Paper›PMID 34419089›Full record

ArticleSubstance abuse treatment, prevention, and policy2021

Naloxone availability in independent community pharmacies in Georgia, 2019.

Lauren Gilbert, Jennifer Elliott, Lauren Beasley, Ekene Oranu, Kimberly Roth, Jennifer Nguyễn

Open access · goldAbstract read
In one paragraph

Article in Substance abuse treatment, prevention, and policy, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
3.3field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 20 citations in OpenAlex.

  1. Trial
  2. Article
  3. Price Sensitivity and Information Barriers to the Take-Up of Naloxone.American economic journal. Economic policy · 2024
    Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Naloxone Accessibility by Standing Order in North Carolina Community Pharmacies.Journal of the American Pharmacists Association : JAPhA
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Lauren GilbertUniversity of Houston College of Medicine, Houston, TX, USA.
Jennifer ElliottMercer University College of Pharmacy, 3001 Mercer University Drive, Atlanta, GA, USA.
Lauren BeasleyMercer University College of Pharmacy, 3001 Mercer University Drive, Atlanta, GA, USA.
Ekene OranuMercer University College of Pharmacy, 3001 Mercer University Drive, Atlanta, GA, USA.
Kimberly RothMercer University School of Medicine, Savannah, GA, USA.
Jennifer NguyễnMercer University College of Pharmacy, 3001 Mercer University Drive, Atlanta, GA, USA. nguyen_jl@mercer.edu.ORCID 0000-0001-5755-5814
Mercer University · USUniversity of Houston · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundIncreasing the availability of naloxone among people who use opioids, and friends and family of past and present people who use opioids is a vitally important mission to reduce the occurrence of opioid-related overdose deaths. The purpose of this study was to determine the availability of naloxone in independent community pharmacies in Georgia. Secondary objectives include determining pharmacists' knowledge regarding the standing order and ability to counsel regarding naloxone.

methodsA cross-sectional study using a secret shopper approach with phone contact was conducted over a period of 10 months. The study was population based and was conducted at all independent pharmacies in the state of Georgia. All independent community pharmacies in the state of Georgia were contacted and asked the naloxone questions with a 96% response rate (n = 520).

resultsFive hundred fifty-eight independent community pharmacies were called, with a 96% response rate (n = 520 pharmacies). Two hundred-twenty pharmacies reported having naloxone in stock. Of the 335 pharmacists asked, 174 (51.9%) incorrectly said that a prescription was required. The mean (SD) cash price was $148.02 (27.40), with a range of $0 to $300. Of 237 pharmacists asked who had naloxone in stock or who stated they could get naloxone in stock, 212 stated that they could demonstrate how to use it, 8 stated they could not, and 17 said that they possibly could or were unsure how to use it.

conclusionsThis study provided insight into the limited availability of naloxone at independent community pharmacies in Georgia after the standing order was issued. The majority of pharmacists at independent pharmacies in Georgia were not using the publicly available state naloxone standing order. Additionally, the low availability of naloxone and its high cost for uninsured individuals are significant structural barriers for reducing opioid-related mortality.

Indexed as

Drug OverdoseOpioid-Related DisordersPharmaciesCross-Sectional StudiesGeorgiaHumansNaloxoneNarcotic AntagonistsPharmacistsNaloxoneNarcotic AntagonistsCommunity pharmacy servicesNaloxoneOpioidsPharmacies

Identifiers

PMID34419089
PMCPMC8379837
OpenAlexW3193304641

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.